RGBP — Regen BioPharma Income Statement
0.000.00%
Last trade - 00:00- $1.74m
- $2.71m
- $0.24m
Annual income statement for Regen BioPharma, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.11 | 0.171 | 0.236 | 0.237 | 0.237 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.319 | 1.15 | 0.67 | 0.922 | 0.654 |
| Operating Profit | -0.209 | -0.976 | -0.435 | -0.686 | -0.417 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3.41 | -6.77 | 2.44 | 1.16 | -0.668 |
| Net Income After Taxes | 3.41 | -6.77 | 2.44 | 1.16 | -0.668 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 3.41 | -6.77 | 2.44 | 1.16 | -0.668 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.73 | -6.77 | 2.44 | 1.02 | -0.668 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.45 | -1.48 | 0.403 | 0.145 | -0.081 |